- Home
- ARQT vs DRH Comparison
ARQT vs DRH Comparison
Compare ARQT & DRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- DRH
- Stock Information
- Founded
- ARQT 2016
- DRH 2004
- Country
- ARQT United States
- DRH United States
- Employees
- ARQT N/A
- DRH N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- DRH Real Estate Investment Trusts
- Sector
- ARQT Health Care
- DRH Real Estate
- Exchange
- ARQT Nasdaq
- DRH Nasdaq
- Market Cap
- ARQT 1.7B
- DRH 1.6B
- IPO Year
- ARQT 2020
- DRH 2005
- Fundamental
- Price
- ARQT $13.82
- DRH $7.62
- Analyst Decision
- ARQT Strong Buy
- DRH Hold
- Analyst Count
- ARQT 6
- DRH 6
- Target Price
- ARQT $18.80
- DRH $8.79
- AVG Volume (30 Days)
- ARQT 1.9M
- DRH 2.8M
- Earning Date
- ARQT 08-13-2025
- DRH 08-07-2025
- Dividend Yield
- ARQT N/A
- DRH 5.51%
- EPS Growth
- ARQT N/A
- DRH N/A
- EPS
- ARQT N/A
- DRH 0.19
- Revenue
- ARQT $212,819,000.00
- DRH $1,128,313,000.00
- Revenue This Year
- ARQT $61.15
- DRH N/A
- Revenue Next Year
- ARQT $37.98
- DRH $2.13
- P/E Ratio
- ARQT N/A
- DRH $40.13
- Revenue Growth
- ARQT 100.03
- DRH 3.73
- 52 Week Low
- ARQT $7.86
- DRH $6.19
- 52 Week High
- ARQT $17.75
- DRH $10.00
- Technical
- Relative Strength Index (RSI)
- ARQT 50.73
- DRH 50.47
- Support Level
- ARQT $12.97
- DRH $7.47
- Resistance Level
- ARQT $13.84
- DRH $7.93
- Average True Range (ATR)
- ARQT 0.61
- DRH 0.18
- MACD
- ARQT 0.02
- DRH -0.01
- Stochastic Oscillator
- ARQT 51.64
- DRH 41.51
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About DRH Diamondrock Hospitality Company
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transients, business transients, and group customers.